This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.
Clinical Trials Arena on MSN2d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMRIn Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
CD38 is found on plasma cells – B-lymphocytes whose main function is to generate antibodies – so, felzartamab could have broad utility in immune-mediated diseases (IMDs) driven by antibody ...
That included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody ... of cancer cells and serum fee light chain biomarkers that indicate a plasma cell cancer.
14d
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback